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Abstract
Background: This study evaluated glucose control by continuous glucose monitoring (CGM) during treatment
with ultra-rapid lispro (URLi) or lispro used in combination with insulin glargine or degludec in adults with
type 1 diabetes in a substudy of the PRONTO-T1D study.
Methods: Ambulatory glucose profiles were evaluated in 269 patients from PRONTO-T1D assigned to double-
blind URLi (n = 97) or lispro (n = 99) given 0–2 min before the start of the meal (mealtime), or open-label URLi
(n = 73) given 20 min after the meal (postmeal URLi). Blinded CGM was used for up to 14 days before baseline
and the 26-week primary endpoint. The primary objective was to compare mealtime URLi and lispro with
respect to incremental area under the serum glucose concentration versus time curve from 0 to 2 h (iAUC0–2h)
after breakfast.
Results: Mealtime URLi was superior in reducing the iAUC0–2h when compared to lispro for breakfast (least
squares mean [LSM] difference -28.1 mg$h/L, P = 0.048) and for all meals combined. iAUC0–3h and iAUC0–4h
were also reduced. Postmeal URLi resulted in similar postprandial glucose (PPG) control to mealtime lispro,
but less optimal PPG control compared to mealtime URLi. Mealtime URLi increased daytime time in range
(71–180 mg/dL [3.9–10.0 mmo/L]) (LSM difference = +43.6 min, P = 0.020) and decreased nighttime time in
hypoglycemia (LSM difference £70 mg/dL [3.9 mmol/L] = -11.5 min, P = 0.009) compared to mealtime lispro.
Conclusions: Results of this CGM substudy support the improved PPG control seen with mealtime URLi in the
PRONTO-T1D study and show that mealtime URLi resulted in improved daytime time in target range.
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Introduction
Use of rapid-acting insulin analogs results in re-duced postprandial hyperglycemia when compared to
human insulin.1 Nevertheless, elevated postprandial glucose
(PPG) is a persistent challenge to diabetes management
among patients with both type 1 diabetes and type 2 diabe-
tes.2,3 Ultra-rapid lispro (URLi) is a novel ultra-rapid insulin
lispro formulation developed to more closely match physio-
logical insulin secretion in response to meals and improve
1Department of Metabolic Diseases, Jagiellonian University Medical College, Krakow, Poland.
2DC and RL Clinical Design, Delivery, and Analytics, TH and JB-V Connected Care and Insulins—Medical Development, Eli Lilly and
Company, Indianapolis, Indiana, USA.
3Endocrinologist and Partner, Atlanta Diabetes Associates, Atlanta, Georgia, USA.
4Endocrinologist and Executive Director, International Diabetes Center, Minneapolis, Minnesota, USA.
Prior Presentation: Parts of this study were presented in abstract form at the 79th Scientific Sessions of the American Diabetes
Association, San Francisco, CA, USA, June 6–11, 2019, at the 46th Annual Meeting and Exhibition of the American Association of
Diabetes Educators, Houston, TX, USA, August 9–12, 2019, the 55th Annual Meeting of the European Association for the Study of
Diabetes, Barcelona, Spain, September 16–20, 2019, and at the 13th International Conference on Advanced Technologies and Treatments
for Diabetes, Madrid, Spain, February 19–22, 2020.
ª Maciej T. Malecki, et al., 2020; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the
Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly credited.
DIABETES TECHNOLOGY & THERAPEUTICS
Volume 22, Number 11, 2020
Mary Ann Liebert, Inc.
DOI: 10.1089/dia.2020.0129
853
PPG control.4 The URLi formulation includes two key lo-
cally acting excipients, treprostinil and citrate, which accel-
erate the absorption of insulin lispro from the site of injection
via independent mechanisms of action. Microdoses of tre-
prostinil in URLi induce local vasodilation, while citrate
increases vascular permeability.5,6 URLi was efficacious
with a similar safety profile to lispro (Humalog) in phase 3
studies7 and type 2 diabetes.8
The PRONTO-T1D study, which evaluated the efficacy
and safety of URLi versus lispro in adults with type 1 diabetes,
met the primary endpoint of noninferior hemoglobin A1c
(HbA1c) change from baseline compared to lispro at 26
weeks, when insulins were dosed at mealtime.7 Noninferiority
for postmeal URLi (administered 20 min after the start of a
meal) versus mealtime lispro was also shown. Mealtime
URLi was superior to mealtime lispro in controlling 1- and 2-h
PPG excursions during standardized test meals. Postmeal
URLi provided similar PPG control during the test meal
compared to mealtime lispro but was less optimal compared
to mealtime URLi. The results of this trial have been pub-
lished.7 The PRONTO-T1D study included a continuous
glucose monitoring (CGM) substudy, the results of which are
reported here.
The aim of this CGM substudy of PRONTO-T1D was to
compare glucose control as measured by CGM during
treatment with URLi or lispro, when either was used in
combination with basal insulin glargine or insulin degludec.
This includes incremental area under the serum glucose
concentration versus time curve (iAUC) after the start of
breakfast and all meals as well as time in target glucose range.
Methods
Study design and treatment
A detailed description of the study design and primary
results has been published.7 In brief, this was a phase 3, treat-
to-target study comparing URLi and lispro as part of a mul-
tiple daily injection regimen in adult patients with type 1
diabetes. Patients were treated with either insulin glargine or
insulin degludec throughout the study in combination with
prandial insulin. Following an 8-week lead-in period for
basal insulin optimization, patients were randomized to one
of three groups and were permitted to use carbohydrate
counting or pattern adjustment to manage prandial insulin
dosing requirements. In two of the treatment groups, URLi
and lispro were administered immediately (0–2 min) before
each meal (mealtime) in a double-blind manner.
A third open-label treatment group consisted of URLi
administered 20 min after the start of a meal (postmeal
URLi). The study was designed to demonstrate noninferiority
of URLi, compared with lispro in change from baseline to
week 26 in HbA1c, when URLi or lispro was administered at
the start of the meal. Blinded CGM was offered to a subgroup
of patients at selected sites in PRONTO-T1D. It was not
mandatory for patients to participate in the CGM substudy;
however, all patients who participated in this substudy had to
meet the inclusion criteria for PRONTO-T1D and partici-
pated in all study visits and procedures.
Adult patients with type 1 diabetes, diagnosed based on the
World Health Organization criteria,9 and continuously using
insulin for ‡1 year were eligible for participation if treated
with a rapid-acting insulin analog ‡90 days and basal insulin
‡30 days before screening, with an HbA1c 7.0%–9.5%
(53.00–80.32 mmol/mol) and body mass index £35 kg/m2.
Patients who participated in PRONTO-T1D were randomly
assigned to mealtime URLi, mealtime lispro, or postmeal
URLi in a 4:4:3 randomization ratio. Stratification for
PRONTO-T1D was by country, HbA1c stratum (£7.5%,
>7.5%), type of basal insulin during the lead-in period,
and prandial insulin dosing plan during the study.7
Blinded CGM (Dexcom G4 Platinum System) was used
for up to 14 days before baseline and the 26-week primary
endpoint. Patients were instructed to mark the start time for
each meal or snack (carb event) and the time for each insulin
injection (insulin event) using the Events feature of the CGM
system, and perform glucose calibration as recommended by
the manufacturer during the CGM sessions.
The study was conducted in accordance with the Interna-
tional Conference on Harmonization Guidelines for Good
Clinical Practice and the Declaration of Helsinki. All patients
provided written informed consent.
Statistical analyses
Raw data were collected for up to 14 days of CGM use.
Prespecified criteria were used to define valid CGM days for
inclusion in analysis as follows:
 For assessments of the 24-h, daytime, or nocturnal
periods, at least 70% of the total measures expected
within that timeframe and no missing period longer
than 3 h was required.
 For mealtime assessments, at least 70% of the total
measures for that meal and no missing period longer
than 20 min for iAUC0–2h (or 25 min for other by-meal
outcome variables) was required.
The primary outcome measurement was the iAUC0–2h
after the start of breakfast at week 26, with iAUC0–2h being
the average of iAUC0–2h values on all valid CGM days and
iAUC0–2h on each day being the total area under the glucose
curve and above the glucose concentration before the start of
breakfast during 0–2 h after the start of breakfast. The iAUCs
for breakfast as well as midday and evening meals were
calculated by applying the trapezoidal rule to both positive
and negative glucose increments.
The area of each small trapezoid was first calculated and then
the iAUC was derived as the total sum of those individual areas.
If any trapezoid fell below the starting glucose, a negative value
was obtained for its area that was in effect subtracted from the
area obtained from above the starting glucose (the average of
the CGM values in the time window [-19, 0] minutes relative to
the start of the meal). Breakfast, lunch, and dinner were defined
as the first carb event during the time intervals of 04:00–11:00 h
(4 am–11 am), 11:00–16:00 h (11 am–4 pm), and 16:00–
21:00 h (4 pm–9 pm), respectively, that was associated with an
insulin event within –30 min. Data from the period up to 4 h for
all meals combined were also analyzed.
Assuming a 20% dropout rate for 26 weeks, *289 patients
(105 in mealtime URLi, 105 in mealtime lispro, and 79 in
postmeal URLi) were planned to participate in this substudy,
providing at least 80% power to show superiority of mealtime
URLi versus mealtime lispro in iAUC0–2h after the start of
breakfast assuming a mean difference of 27 mg$h/dL and a
standard deviation (SD) of 62 mg$h/dL.
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All patients who were enrolled in this substudy and were
randomized to one of the study treatments, received at least
1 dose of study treatment, and had CGM data from at least 1
collection period (either baseline or endpoint) included in the
analyses.
Statistical comparisons were based on a two-sided signif-
icance level of 0.05. There was no multiplicity adjustment.
For PPG-related variables (postmeal iAUC, postmeal glu-
cose excursions), the percentage of patients with baseline
missing was >20% (mostly due to missing meal event mark-
ers); thus, as prespecified, a constrained longitudinal data
analysis was performed.10,11
Hypoglycemia/hyperglycemia rate as measured by CGM
data was analyzed using a negative binomial regression
model and the proportion of patients with at least 1 hypo-
glycemia/hyperglycemia event as measured by CGM data
(incidence) was analyzed using a logistic regression model,
with a hypoglycemia/hyperglycemia event defined as at least
10 consecutive minutes below/above the specified thresh-
old and determined by 3 or more consecutive CGM values
meeting the criterion. For other CGM variables (glycemic
variability, average daily glucose, daily average AUC,
hourly average glucose), an analysis of covariance model
was used. For continuous variables, the baseline value was
included as a covariate in the analysis models to account for
potential baseline imbalance in this substudy, and stratifi-
cation factors without severe imbalance were used as fixed
effects.
The glucose thresholds prespecified for calculation of
various time in range (TIR) parameters in this study were
different from those recommended in newer consensus
guidelines.12 As a result, data were reanalyzed using recent
thresholds (for example TIR from 70–180 mg/dL and time in
hypoglycemia <70 mg/dL and <54 mg/dL) and results of




A total of 388 patients signed the informed consents for
both the main study and the CGM substudy, and 313 of these
patients were randomized. Ambulatory glucose profiles
(AGPs) were evaluated in 269 patients from PRONTO-T1D
assigned to mealtime URLi (n = 97), mealtime lispro (n = 99),
and postmeal URLi (n = 73). Patient disposition was similar
between treatment groups with *94% of patients overall
completing study treatment as part of the CGM cohort (Sup-
plementary Table S1). A detailed description of patient dis-
position for the main study population has been published.7
Demographics and key non-CGM-related study results
Baseline characteristics were similar between treatment
groups in the CGM cohort (Supplementary Table S2) and
representative of the main study cohort in PRONTO-T1D.7
In general, the results from key glycemic control param-
eters in the CGM population were consistent with the full
study population indicating that the CGM population was




Figure 1A presents the AGPs by meal for each treatment
group showing the median glucose control line, the 25th to
75th percentile lines, and the 10th to 90th percentile lines
over 4 h after each meal. Figure 1B presents the mean glucose
profile over 4 h from each meal from the AGPs. Visual ex-
amination of these AGPs showed that mealtime URLi was
associated with smaller PPG excursions compared to meal-
time lispro. In addition, postmeal URLi was associated with
more variable PPG excursions compared to mealtime URLi
and mealtime lispro.
iAUC after meals
URLi administered immediately before breakfast resulted
in a statistically significant reduction in the iAUC0–2h after
breakfast (least squares mean [LSM] difference -28.1 mg$h/L,
P = 0.048) when compared to mealtime lispro and remained
statistically significantly lower for both iAUC0–3h and
iAUC0–4h (Fig. 1C). Similarly, the iAUC0–2h, iAUC0–3h,
and iAUC0–4h for all meals combined were statistically
significantly lower in the mealtime URLi group compared
to the mealtime lispro group (Fig. 1C).
For breakfast and all meals combined, there were no sta-
tistically significant treatment differences between the post-
meal URLi and mealtime lispro group in PPG iAUC for any
time interval. The results in the postmeal URLi versus
mealtime URLi group were comparable for all breakfast meal
comparisons, but for all meals combined, the iAUC0–2h and
iAUC0–3h were statistically significantly higher in the post-
meal URLi versus the mealtime URLi group (Fig. 1C).
Postmeal glucose excursions
Consistent with the AGPs, mealtime URLi statistically
significantly reduced postmeal glucose excursions compared
to mealtime lispro up to 3 h for all meals combined (Table 1).
There were no statistically significant differences in postmeal
glucose excursions between postmeal URLi and mealtime
lispro but postmeal URLi demonstrated statistically signifi-
cantly increased postmeal glucose excursions compared to
mealtime URLi up to 2 h for all meals combined. There were
no statistically significant treatment differences in time to
postmeal maximum glucose excursion (Table 1).
Time in ranges
During the daytime period, mealtime URLi use was as-
sociated with increased TIR (71–180 mg/dL) compared to
mealtime lispro (LSM difference = 43.6 min; P = 0.020)
(Fig. 2). Lowering of daytime time above range (>180 mg/dL)
and time below range with mealtime URLi did not achieve
statistical significance compared to mealtime lispro (LSM
differences of -41.2 min and -3.9 min, respectively) (Fig. 2).
Postmeal URLi was associated with a significantly decreased
time in hypoglycemia (<50 mg/dL) compared to mealtime
lispro (LSM difference = -9.4 min; P = 0.010) (Fig. 2); how-
ever, it was also associated with a significantly increased time
above range compared to mealtime URLi (LSM differ-
ence = 63.2 min; P = 0.009) (Fig. 2).
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During the 24-h period, mealtime URLi statistically sig-
nificantly increased TIR (71–180 mg/dL) and statistically
significantly decreased time above range compared to post-
meal URLi (Table 1). Postmeal URLi statistically signifi-
cantly decreased time in hypoglycemia (£70, <54, and
<50 mg/dL) compared to mealtime lispro (Table 1; Supple-
mentary Table S4).
During the nighttime period, there were no statistically
significant treatment differences between all three treatment
arms in TIR (71–180 mg/dL) (Supplementary Table S4).
Postmeal URLi statistically significantly increased time
above range compared to mealtime lispro (Supplementary
Table S4). Mealtime URLi and postmeal URLi statistically
significantly decreased time in hypoglycemia (£70 and
<54 mg/dL) compared to mealtime lispro (Supplementary
Table S4); however, these improvements in hypoglycemia
risk were associated with higher hourly average glucose
during the nighttime period (Fig. 3).
Mean daily glucose profiles
Figure 3 illustrates hourly average glucose by CGM
for each treatment group over 24 h at week 26. At mul-
tiple timepoints throughout the daytime period, mealtime
URLi resulted in statistically significantly lower day-
time glucose compared to mealtime lispro consistent with
the demonstrated improvements in PPG, but overnight
glucose was consistently, but not statistically signifi-
cantly, higher than mealtime lispro. Postmeal URLi re-
sulted in statistically significantly higher glucose at
multiple timepoints during the nocturnal period com-
pared to mealtime lispro.
FIG. 1. Mealtime and postmeal glucose control. (A) Ambulatory glucose profiles (median and percentile) by treatment
group 0–4 h postmeal at week 26. (B) Ambulatory glucose profiles (mean) by treatment group 0–4 h postmeal at week 26.
(C) Incremental glucose AUC postbreakfast and all postmeals combined. AUC, area under the curve; iAUC, incremental
AUC; IQR, interquartile range; n, number of subjects who had valid continuous glucose monitoring data per prespecified
criteria; URLi, ultra-rapid insulin lispro.
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Average daily glucose was similar in the mealtime URLi
and mealtime lispro groups, but statistically significantly
higher in the postmeal URLi group compared to the mealtime
URLi group (Table 1). Mealtime URLi resulted in similar
daily average AUC glucose compared to mealtime lispro for
the daytime, nighttime, and 24-h period (Table 1; Supple-
mentary Fig. S1). Postmeal URLi resulted in statistically sig-
nificantly higher daily AUC compared to mealtime lispro for
the nighttime period and compared to mealtime URLi for the
daytime and 24-h period (Table 1; Supplementary Fig. S1).
Glucose variability
Conventional measures of within-day, between-day, and
overall glycemic variability (such as coefficient of variation,
SD, mean absolute glucose excursion [MAGE], mean of
Table 1. Summary of Key Glycemic Control Parameters at Week 26
Parameter (unit) Treatment n LSM (SE)
LSM difference (95% CI), P-value
A: Mealtime URLi vs. mealtime lispro
B: Postmeal URLi vs. mealtime lispro
C: Postmeal URLi vs. mealtime URLi
HbA1c (%) Mealtime lispro 95 7.12 (0.06) A: 0.02 (-0.11 to 0.16), P = 0.733
Mealtime URLi 91 7.15 (0.06) B: 0.23 (0.08 to 0.37), P = 0.003
Postmeal URLi 72 7.35 (0.06) C: 0.20 (0.05 to 0.35), P = 0.007
HbA1c (mmol/mol) Mealtime lispro 95 54.4 (0.63) A: 0.3 (-1.2 to 1.8), P = 0.733
Mealtime URLi 91 54.6 (0.64) B: 2.5 (0.9 to 4.1), P = 0.003
Postmeal URLi 72 56.8 (0.70) C: 2.2 (0.6 to 3.8), P = 0.007
Average daily glucose (mg/dL) Mealtime lispro 81 169.4 (3.83) A: -2.9 (-10.8 to 5.0), P = 0.474
Mealtime URLi 84 166.5 (3.58) B: 7.0 (-1.5 to 15.5), P = 0.104
Postmeal URLi 66 176.4 (3.93) C: 9.9 (1.5 to 18.3), P = 0.021
Average daily glucose (mmol/L) Mealtime lispro 81 9.54 (0.211) A: -0.42 (-0.86 to 0.03), P = 0.066
Mealtime URLi 84 9.12 (0.199) B: 0.19 (-0.28 to 0.67), P = 0.424
Postmeal URLi 66 9.73 (0.220) C: 0.61 (0.14 to 1.08), P = 0.012
Daily average AUC (mg$h/dL) Mealtime lispro 81 4065.5 (91.43) A: -66.0 (-255.2 to 123.2), P = 0.492
Mealtime URLi 84 3999.5 (85.64) B: 164 (-39.2 to 367.2), P = 0.113
Postmeal URLi 66 4229.5 (93.98) C: 230.0 (28.4 to 431.6), P = 0.026
Daily average AUC (mmol$h/dL) Mealtime lispro 81 225.9 (5.08) A: -3.7 (-14.2 to 6.8), P = 0.492
Mealtime URLi 84 222.2 (4.76) B: 9.1 (-2.2 to 20.4), P = 0.113
Postmeal URLi 66 235.0 (5.22) C: 12.8 (1.6 to 24.0), P = 0.026
24-h TIR 71–180 mg/dL
(3.9–10.0 mmol/L),
minutes [% of time]
Mealtime lispro 81 754.8 (23.36) [52.4] A: 32.0 (-16.8 to 80.8), P = 0.197
Mealtime URLi 84 786.8 (21.74) [54.6] B: -22.8 (-74.6 to 29.0), P = 0.386
Postmeal URLi 66 732.0 (24.27) [50.8] C: -54.8 (-106.3 to -3.3), P = 0.037
24-h Time >180 mg/dL
(10.0 mmol/L), minutes
[% of time]
Mealtime lispro 81 557.6 (28.73) [38.7] A: -18.9 (-78.2 to 40.4), P = 0.531
Mealtime URLi 84 538.7 (26.66) [37.4] B: 55.7 (-7.7 to 119.1), P = 0.085
Postmeal URLi 66 613.3 (29.47) [42.6] C: 74.6 (11.8 to 137.4), P = 0.020
24-h Time <50 mg/dL
(2.8 mmol/L), minutes
[% of time]
Mealtime lispro 81 40.6 (4.78) [2.8] A: -9.6 (-19.8 to 0.5), P = 0.062
Mealtime URLi 84 31.0 (4.50) [2.2] B: -14.3 (-25.2 to -3.5), P = 0.010
Postmeal URLi 66 26.3 (5.03) [1.8] C: -4.7 (-15.5 to 6.1), P = 0.394
Within day variability CV (%) Mealtime lispro 81 38.4 (0.74) A: -0.6 (-2.2 to 1.0), P = 0.449
Mealtime URLi 84 37.8 (0.70) B: -1.1 (-2.8 to 0.6), P = 0.205
Postmeal URLi 66 37.3 (0.78) C: -0.5 (-2.2 to 1.2), P = 0.575
Between day variability CV (%) Mealtime lispro 81 41.1 (0.72) A: -0.6 (-2.1 to 0.9), P = 0.446
Mealtime URLi 84 40.5 (0.68) B: -1.4 (-3.1 to 0.2), P = 0.092
Postmeal URLi 64 39.7 (0.77) C: -0.8 (-2.5 to 0.8), P = 0.323
Postmeal glucose
excursion 0–2 h (mg/dL)
Mealtime lispro 54 19.3 (3.37) A: -10.9 (-19.5 to -2.4), P = 0.013
Mealtime URLi 56 8.4 (3.29) B: 3.8 (-5.1 to 12.6), P = 0.401
Postmeal URLi 48 23.1 (3.58) C: 14.7 (5.9 to 23.5), P = 0.001
Postmeal glucose
excursion 0–2 h (mmol/L)
Mealtime lispro 54 1.1 (0.19) A: -0.6 (-1.1 to -0.1), P = 0.013
Mealtime URLi 56 0.5 (0.18) B: 0.2 (-0.3 to 0.7), P = 0.401
Postmeal URLi 48 1.3 (0.20) C: 0.8 (0.3 to 1.3), P = 0.001
Postmeal glucose
excursion 0–3 h (mg/dL)
Mealtime lispro 54 19.8 (4.14) A: -13.2 (-23.7 to -2.7), P = 0.014
Mealtime URLi 55 6.7 (4.12) B: -2.5 (-13.4 to 8.3), P = 0.645
Postmeal URLi 48 17.3 (4.40) C: 10.6 (-0.2 to 21.5), P = 0.054
Postmeal glucose
excursion 0–3 h (mmol/L)
Mealtime lispro 54 1.1 (0.23) A: -0.7 (-1.3 to -0.1), P = 0.014
Mealtime URLi 55 0.4 (0.23) B: -0.1 (-0.7 to 0.5), P = 0.645
Postmeal URLi 48 1.0 (0.24) C: 0.6 (-0.0 to 1.2), P = 0.054
Time to maximum postmeal
glucose excursion
0–3 h, minutes
Mealtime lispro 54 85.7 (3.35) A: -5.4 (-13.8 to 3.0), P = 0.207
Mealtime URLi 55 80.3 (3.34) B: -7.9 (-16.6 to 0.7), P = 0.072
Postmeal URLi 48 77.7 (3.55) C: -2.5 (-11.2 to 6.1), P = 0.562
AUC, area under the curve; CI, confidence interval; CV, coefficient of variation; HbA1c, hemoglobin A1c; LSM, least squares mean;
n, number of subjects; SE, standard error; TIR, time in range; URLi, ultra-rapid insulin lispro.
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daily differences) defined for the 24-h, daytime, and night-
time periods showed that mealtime URLi had similar vari-
ability to mealtime lispro (Table 1; Supplementary Table S5).
Postmeal URLi had greater variability by some of these
measures, compared to mealtime lispro (low blood glucose
index) and mealtime URLi (MAGE, high blood glucose in-
dex) (Table 1; Supplementary Table S5).
Discussion
URLi and lispro demonstrated similar HbA1c reduction in
the main PRONTO-T1D study7 and the same was true in this
CGM substudy. However, HbA1c provides an incomplete
picture of daily fluctuations in glycemic control, such as PPG
and TIR, which are important to patients.12 In a large study of
patients with type 1 diabetes and type 2 diabetes (n = 1200),
Heller et al. found that increased severity and frequency of
acute postprandial hyperglycemia is associated with greater
burden and experience of symptoms and can negatively im-
pact daily functioning of patients.13 CGM-based measures
such as TIR provide additional information that patients can
use to understand how their insulin, meals, and exercise af-
fect glycemic control. TIR was also identified as one of the
‘‘biggest drivers of improved diabetes management and
mindset,’’ and ranked only behind food choice as having the
biggest impact on daily life in a survey of 3461 people with
type 1 diabetes or type 2 diabetes.14
In this substudy of PRONTO-T1D, blinded CGM was
offered to a subgroup of patients in each of the three treatment
groups to provide additional information related to PPG
control, TIR, and glycemic variability. The primary objective
of this CGM substudy was achieved as mealtime URLi use
was characterized by lower iAUC0–2h when compared to
mealtime lispro, and this superiority was also shown for the
FIG. 2. Daytime time in ranges at week 26 (6:00 am–midnight). CI, confidence interval; LSM, least squares mean.
FIG. 3. Hourly average glucose during continuous glucose monitoring at week 26. Data are LSM – SE. *P < 0.05 for
mealtime URLi versus mealtime lispro, {P < 0.05 for postmeal URLi versus mealtime lispro, {P < 0.05 for postmeal URLi
versus mealtime URLi. n, number of subjects; SE, standard error.
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comparisons of the iAUC0–3h and iAUC0–4h. Results from the
ambulatory PPG assessments demonstrating also improved
PPG control and reduced PPG excursions during treatment
with mealtime URLi are consistent with observations from
both the mixed-meal tolerance test and 10-point SMBG
profiles in the main study.7
One potential limitation of these comparisons of mealtime
URLi and lispro relates to the inability to optimize timing of
administration relative to the start of the meal based on their
unique time-action profiles and still maintain the rigor af-
forded by double-blind treatment. Although administration
of insulin lispro is recommended within 15 min before a
meal, it is generally recognized that optimal effects are seen
when rapid insulin analogs are given 15–20 min before a
meal, survey data from the T1D Exchange examining the
time of prandial insulin administration relative to meals (‘‘On
average, when do you take your insulin in relation to meal-
time?’’ asked on March 8, 2014) showed that only 16.3% of
patients who responded indicated that they inject 15 min
before meals (T1D Exchange, email communication, April
29, 2020).
Results from a prior phase 1 test meal study in patients with
T1D demonstrated that URLi performed better than lispro
(glucose AUC0–2h) when both were administered 15 min
before the meal.15 Based on these considerations, both
mealtime URLi and lispro were administered 0–2 min before
the start of the meal in the current study to facilitate double
blinding and to minimize potential postprandial hypoglyce-
mia risk with URLi in an outpatient setting.
The improvements in PPG control observed in mealtime
URLi patients were accomplished without an increase in time
below range versus the mealtime lispro group. In fact,
mealtime URLi was associated with an increased time spent
in target glycemic range during the daytime period, which is
the period when prandial insulins are typically used. This
observation is especially notable because the overall gly-
cemic control achieved in these treatment groups was good
and quite similar.
Mealtime URLi patients also spent statistically signifi-
cantly less time in hypoglycemia during the nighttime period
(<50 mg/dL [2.8 mmol/L] and (£70 mg/dL [3.9 mmol/L])
compared to the mealtime lispro group; although these
findings were associated with numerically higher nocturnal
hourly average glucose during treatment with mealtime
URLi. This contrasts with the main study, where no statisti-
cally significant treatment differences were detected in the
rate or incidence of nocturnal hypoglycemia7 and were very
likely related to the greater sensitivity of CGM for the as-
sessment of hypoglycemia occurrence,16 which does not
depend on patient’s symptoms for detection. Visual inspec-
tion of AGPs representing the 4-h postmeal intervals and
the mean glucose profiles (Fig. 1A, B) shows reduced glu-
cose excursions postmeals (confirmed by postmeal AUC
measurements).
Postmeal URLi did not demonstrate statistically significant
differences in PPG control or TIR compared to mealtime
lispro; however, it resulted in larger postmeal excursions, less
time in target glycemic range, and more time in hypergly-
cemia compared to mealtime URLi, especially during the
daytime. CGM monitoring provided the opportunity to detect
increases in time spent in hyperglycemia or decreases in time
spent in hypoglycemia in the postmeal URLi arm that were
not possible with conventional blood glucose monitoring and
may help guide the appropriate use of postmeal dosing. While
postmeal URLi administration was shown to be a safe and
efficacious option in the PRONTO-T1D study, it may not be
optimal in most patients and should probably be reserved for
special situations (e.g., when premeal glucose is low or meal
consumption is unpredictable).
In general, this CGM substudy provided insight into am-
bient glucose in an unbiased, ad libitum feeding, ambulatory
setting that adds to the body of evidence that URLi admin-
istered at the start of the meal provides superior PPG control
compared to mealtime lispro. These AGPs also provide in-
sight into the time patients spent in target range and a thor-
ough, reassuring assessment of hypoglycemia that was not
dependent on patient self-reporting.
The results of this substudy also suggest possible avenues
for further optimization of dosing with URLi. For example,
Figure 3 clearly demonstrates improved daytime glycemia
with mealtime URLi compared to lispro. However, mean
glucose levels were lower with lispro during the overnight
period. It is therefore possible that additional titration of basal
insulin or use of a closed-loop insulin delivery system could
improve overall glycemic control with the use of URLi.
These possibilities should be explored in future studies.
In conclusion, during the daytime period, URLi adminis-
tered immediately before meals resulted in better PPG con-
trol, increased time spent in target range, and no increases in
time spent in hypoglycemia compared to mealtime lispro
even though both groups reported similar HbA1c after 26
weeks of treatment. URLi administered 20 min after the start
of the meal was similar to mealtime lispro, but less optimal
than mealtime URLi in managing PPG when these insulins
were administered immediately before meals. Results from
this CGM substudy support key observations from the main
study and suggest that URLi administered before the start of
meals may favorably influence PPG and other glycemic pa-
rameters ‘‘beyond HbA1c’’ that are important to patients.
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